JP2006528949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528949A5 JP2006528949A5 JP2006529827A JP2006529827A JP2006528949A5 JP 2006528949 A5 JP2006528949 A5 JP 2006528949A5 JP 2006529827 A JP2006529827 A JP 2006529827A JP 2006529827 A JP2006529827 A JP 2006529827A JP 2006528949 A5 JP2006528949 A5 JP 2006528949A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- agent
- patients
- therapeutic agent
- valsartan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 4
- 229960004699 valsartan Drugs 0.000 claims 4
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47113703P | 2003-05-16 | 2003-05-16 | |
| US60/471,137 | 2003-05-16 | ||
| PCT/EP2004/005204 WO2004101535A1 (en) | 2003-05-16 | 2004-05-14 | Pharmaceutical composition comprising valsartan |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006528949A JP2006528949A (ja) | 2006-12-28 |
| JP2006528949A5 true JP2006528949A5 (https=) | 2007-06-28 |
| JP4783733B2 JP4783733B2 (ja) | 2011-09-28 |
Family
ID=33452429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006529827A Expired - Fee Related JP4783733B2 (ja) | 2003-05-16 | 2004-05-14 | バルサルタンを含む医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070054947A1 (https=) |
| EP (1) | EP1631556A1 (https=) |
| JP (1) | JP4783733B2 (https=) |
| CN (1) | CN1816533A (https=) |
| AU (2) | AU2004238546A1 (https=) |
| BR (1) | BRPI0410374A (https=) |
| CA (1) | CA2525665A1 (https=) |
| MX (1) | MXPA05012299A (https=) |
| TW (1) | TW200509909A (https=) |
| WO (1) | WO2004101535A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080066776A (ko) * | 2005-11-08 | 2008-07-16 | 노파르티스 아게 | 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물 |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| EP3178812A1 (en) * | 2010-11-12 | 2017-06-14 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| WO2013147137A1 (ja) * | 2012-03-30 | 2013-10-03 | 味の素株式会社 | 心不全の治療剤 |
| AU2013304949C1 (en) | 2012-08-24 | 2020-12-24 | Novartis Ag | NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| ES2968541T3 (es) * | 2013-08-26 | 2024-05-10 | Novartis Ag | Tratamiento de enfermedades cardiovasculares |
| CN106414416B (zh) * | 2014-09-09 | 2020-03-27 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
| WO2019241519A1 (en) * | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition |
| WO2019241590A1 (en) * | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition |
| CN115317478B (zh) * | 2022-08-26 | 2023-05-02 | 宁波大学 | 沙库巴曲缬沙坦类物质在制备药物成瘾和复吸药物的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6201002B1 (en) * | 1997-01-10 | 2001-03-13 | Merck & Co., Inc. | Method for reducing mortality with an angiotensin II antagonist |
| US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| TR200100062T2 (tr) * | 1998-07-10 | 2001-06-21 | Novartis Ag | Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu |
| US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| CA2360305A1 (en) * | 1999-02-09 | 2000-08-17 | Bristol-Myers Squibb Company | Lactam inhibitors of fxa and method |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US6544981B2 (en) * | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| EP1332131A2 (en) * | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| WO2002053161A1 (en) * | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| US6395782B1 (en) * | 2001-03-02 | 2002-05-28 | Wisconsin Alumni Research Foundation | Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid |
| EP1406611A2 (en) * | 2001-05-30 | 2004-04-14 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| JP2005509631A (ja) * | 2001-10-18 | 2005-04-14 | ノバルティス アクチエンゲゼルシャフト | Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩 |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
-
2004
- 2004-05-14 WO PCT/EP2004/005204 patent/WO2004101535A1/en not_active Ceased
- 2004-05-14 BR BRPI0410374-2A patent/BRPI0410374A/pt not_active IP Right Cessation
- 2004-05-14 US US10/556,260 patent/US20070054947A1/en not_active Abandoned
- 2004-05-14 CN CNA2004800186113A patent/CN1816533A/zh active Pending
- 2004-05-14 AU AU2004238546A patent/AU2004238546A1/en not_active Abandoned
- 2004-05-14 MX MXPA05012299A patent/MXPA05012299A/es unknown
- 2004-05-14 TW TW093113753A patent/TW200509909A/zh unknown
- 2004-05-14 CA CA002525665A patent/CA2525665A1/en not_active Abandoned
- 2004-05-14 EP EP04732990A patent/EP1631556A1/en not_active Withdrawn
- 2004-05-14 JP JP2006529827A patent/JP4783733B2/ja not_active Expired - Fee Related
-
2008
- 2008-11-20 AU AU2008246267A patent/AU2008246267B2/en not_active Ceased
- 2008-12-22 US US12/341,669 patent/US20090105322A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512406A5 (https=) | ||
| JP3018160B2 (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤 | |
| US9034909B2 (en) | Use of organic compound for the treatment of Noonan Syndrome | |
| JP2006528949A5 (https=) | ||
| ES2671926T3 (es) | Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico | |
| US20100168238A1 (en) | Pharmaceutical composition containing phloroglucinol and paracetamol | |
| EP4344701A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
| JPH02138123A (ja) | 心不全治療用医薬組成物 | |
| CZ79593A3 (en) | Antitussive preparation | |
| CA3067986A1 (en) | Combined medicinal preparation for treating viral infections | |
| JP2010163426A (ja) | ホスホジエステラーゼ５阻害剤とアルギニンを含有する医薬組成物 | |
| JP2011093890A (ja) | 鼻汁分泌抑制用組成物 | |
| JPS6058726B2 (ja) | プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤 | |
| KR100379155B1 (ko) | 새로운 진통제 조성물 | |
| EP3790550A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure | |
| US3073744A (en) | Therapeutic compositions against virus diseases | |
| Upadhyay et al. | Studies on Formulation and optimization of Gastro Retentive multi-Particulates of Glibenclamide and Metformin hydrochloride for the treatment of Type II Diabetes mellitus using Gelucire: A Review | |
| JP2621382B2 (ja) | 尿酸排泄剤 | |
| JPS6116A (ja) | 有機化合物に関する改良 | |
| JP3254712B2 (ja) | 医薬組成物 | |
| JPH05262747A (ja) | 潰瘍性大腸炎治療剤 | |
| TW202606681A (zh) | 紫質症之預防或治療劑 | |
| KR20260019468A (ko) | 위식도 역류 질환(gerd) 치료를 위한 리나프라잔 글루레이트 | |
| JP2024521354A5 (ja) | 多剤混合薬又は医薬組成物 |